| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S89232-5mg买3赠1 |
99.40% | ￥952.00 |
6 | - | - | - | - |
|
S89232-10mg买3赠1 |
99.40% | ￥1560.00 |
6 | - | - | - | - |
|
S89232-25mg买3赠1 |
99.40% | ￥3060.00 |
5 | - | - | - | - |
|
S89232-100mg |
≥98% | ￥7200.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of beta coronaviruses. Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | IC50: 19.6 μM (SARS-CoV-2);SARS-CoV | ||||||||||||||||||||
| 体外研究： | Merafloxacin (5-80 μM) dose-dependently inhibits programmed -1 ribosomal frameshifting (-1 PRF) of SARS-CoV-2, SARS-CoV, hCoVO-C43, and hCoV-HKU1, with IC50s of 19.6 μM, 19.5 μM, 29.7 μM, and 38.6 μM, respectively | ||||||||||||||||||||
| 参考文献： | 1. Sun Y, et, al. Restriction of SARS-CoV-2 Replication by Targeting Programmed -1 Ribosomal Frameshifting In Vitro. bioRxiv. 2020 Oct 21;2020.10.21.349225. 2. Mandell W, et, al. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents. Antimicrob Agents Chemother. 1986 May;29(5):852-7. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京